|
gptkbp:instanceOf
|
gptkb:drug
NMDA receptor antagonist
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06DX01
|
|
gptkbp:brand
|
gptkb:Namenda
|
|
gptkbp:CASNumber
|
41100-52-1
|
|
gptkbp:chemicalFormula
|
C12H21N
|
|
gptkbp:contraindication
|
hypersensitivity to memantine
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:drugClass
|
antidementia agent
|
|
gptkbp:eliminationHalfLife
|
60-80 hours
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
memantine
|
|
gptkbp:interactsWith
|
gptkb:amantadine
gptkb:dextromethorphan
gptkb:ketamine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
NMDA receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
45%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
confusion
constipation
dizziness
headache
|
|
gptkbp:synonym
|
1-amino-3,5-dimethyladamantane
|
|
gptkbp:usedFor
|
gptkb:Alzheimer's_disease
moderate to severe dementia
|
|
gptkbp:bfsParent
|
gptkb:Alzheimer's_disease
|
|
gptkbp:bfsLayer
|
4
|
